ZUNVEYL (Benzgalantamine Gluconate) Patent Expiration, LOE Window & CMS Spending

ZUNVEYL (Benzgalantamine Gluconate) by Alpha Cognition: FDA Orange Book core substance LOE 2044-02-26 (last listed 2045-07-23), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAlpha Cognition
FDA Application & PathwayN218549 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2044-02-26
Last Listed Patent or Exclusivity Date2045-07-23
Orange Book Patents (*PED Extensions)12 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 16.1% 2-yr change)